Sorafenib, a multi-kinase inhibitor (MKI), inhibits the progression in HCC by blocking the Ras/Raf/MAPK pathway and has demonstrated a significant improvement in the clinical outcome of patients with advanced HCC [4]. Here, RAF1 is linked to hepatocellular carcinoma.